Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.

Abstract: The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a dosage of from 25 kBq to 400 kBq/kg of body weight of said patient or wherein the effective amount of said one or more Ac-225-radiopharmaceuticals is administered as a unitary dosage of from 3 MBq to 30 MBq to said patient.

Abstract: A method is described for producing a radioconjugate labeled with radionuclide Ac-225 comprising the step of chelating said radionuclide Ac-225 with a conjugated chelate compound in a chelation reaction mixture to obtain a radioconjugate labeled with Ac-225, wherein the pH of the chelation reaction mixture is comprised between 7.1 and 10, preferably between 8.0 and 9.5, more preferably about 9.0.

Abstract: Methods of using Th-226 or mother radionuclides thereof, namely U-230 or Th-226, in medicine. These radionuclides are particularly appropriate for the treatment of human and/or non-human mammals, in particular for therapeutic, diagnostic (detection/imaging), prophylactic and pain palliation purposes. These radionuclides may be used in various forms for treatment and/or diagnostic purposes, in particular in cationic form or in the form of radioconjugates or bone-targeting complexes. Methods of making such radionuclides.

Abstract: Methods of using Th-226 or mother radionuclides thereof, namely U-230 or Th-226, in medicine. These radionuclides are particularly appropriate for the treatment of human and/or non-human mammals, in particular for therapeutic, diagnostic (detection/imaging), prophylactic and pain palliation purposes. These radionuclides may be used in various forms for treatment and/or diagnostic purposes, in particular in cationic form or in the form of radioconjugates or bone-targeting complexes. Methods of making such radionuclides.

Abstract: A method for activating particles for internal radiopharmaceutical use, said particles comprising precursor nuclides to be activated, is disclosed. The method comprises: directing a high-intensity laser beam onto converting means to produce an irradiating field; and irradiating said particles comprising precursor nuclides in said irradiating field to activate said precursor nuclides, thereby obtaining radiolabeled particles.

Abstract: The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2 W is —(CH2)m— m is an integer from 1 to 10.

Abstract: A method for producing Ac-225 is presented, wherein Ac-225 is produced by bombardment of Ra-226 with deuterons accelerated in a cyclotron. The deuterons preferably have an incident energy of between 15 and 22 MeV. The method, which allows production of Ac-225 at high yields and purity levels, is particularly interesting in view of Bi-213 generation.

Abstract: The invention concerns a ligand comprising (I) wherein n is an integer from 1 to 5 Y is CO2H or PO3H2T represents —X or -phenyl-X, wherein X represents NO2, NH2, NCS, NHCOCH2-Z, NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or NHCO(CH2)m-Q where Q is a hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, W is —(CH2)m- m is an integer from 1 to 10 Z is chloride, bromide or iodine

Abstract: A method for producing Ac-225 is presented, wherein Ac-225 is produced by bombardment of Th-232 with hydrogen isotope nuclei accelerated in a cyclotron. The method, which allows production of Ac-225 at high yields and purity levels, is particularly interesting for the supply or Ac-225 or of the daughter Bi-213 for medical applications.

Abstract: The invention relates to a method of loading a mother radionuclide into a radionuclide generator which comprises an cation exchange material, the said method comprising a preliminary step which consists in passing over said material a solution containing the mother radionuclide and a complexing agent for said radionuclide, said complexing agent being at an effective concentration so as to prevent the mother radionuclide from concentrating solely in one part of the volume of the cation exchange material, the cation exchange material being chosen in the group consisting of the macroporous resins and the resins having a crosslinking rate of from 1 to 12%. This method is applied to radioisotope generators which emit ? particles and are used in particular in the field of radiotherapy.

Abstract: The invention concerns a ligand comprising (I) wherein n is an integer from 1 to 5 Y is CO2H or PO3H2T represents —X or -phenyl-X, wherein X represents NO2, NH2, NCS, NHCOCH2-Z, NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or NHCO(CH2)m-Q where Q is a hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, W is —(CH2)m- m is an integer from 1 to 10 Z is chloride, bromide or iodine.

Abstract: The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)?m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2 W is —(CH2)m— m is an integer from 1 to 10. Z is chloride, bromide or iodine.

Abstract: This invention relates to a method and an apparatus for preparing Bi-213 to be integrated in a radioimmunocojugate for human therapeutic use. According to the invention the method comprises the sequence of steps as follows: a) an ampoule 5 containing colloid-free actinium-225, obtained from drying an actinium nitrate solution, is loaded into a container 20 provided with radiation panels 21; b) a dissolving medium is poured into the ampoule 5; c) the solution obtained in the ampoule is transferred into an ion exchange column 6; d) an elution medium is circulated through the column 6; e) the eluate containing eluted Bi-213 is pumped towards a vial 10 for quantification and quality control.

Abstract: This invention refers to a method for producing Actinium-225, comprising the steps of preparing a target (1) containing Radium-226, of irradiating this target with protons in a cyclotron and of chemically separating Actinium from the irradiated target material thereafter. According to the invention the proton energy in the cyclotron is adjusted such that the energy incident on the Ra-226 is between 10 and 20 MeV, preferably between 9 14 and 17 MeV. By this means the yield of production of the desired isotope Ac-225 is enhanced with respect to other radioisotopes.